Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity

Bryan A. Johnson, Adam Hage, Birte Kalveram, Megan Mears, Jessica A. Plante, Sergio E. Rodriguez, Zhixia Ding, Xuemei Luo, Dennis Bente, Shelton S. Bradrick, Alexander N. Freiberg, Vsevolod Popov, Ricardo Rajsbaum, Shannan Rossi, William K. Russell, Vineet D. Menachery

Research output: Contribution to journalArticle

Abstract

Enteric viruses exploit bacterial components, including lipopolysaccharides (LPS) and peptidoglycan (PG), to facilitate infection in humans. Because of their origin in the bat enteric system, we wondered if severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome CoV (MERS-CoV) also use bacterial components to modulate infectivity. To test this question, we incubated CoVs with LPS and PG and evaluated infectivity, finding no change following LPS treatment. However, PG from Bacillus subtilis reduced infection >10,000-fold, while PG from other bacterial species failed to recapitulate this. Treatment with an alcohol solvent transferred inhibitory activity to the wash, and mass spectrometry revealed surfactin, a cyclic lipopeptide antibiotic, as the inhibitory compound. This antibiotic had robust dose- and temperature-dependent inhibition of CoV infectivity. Mechanistic studies indicated that surfactin disrupts CoV virion integrity, and surfactin treatment of the virus inoculum ablated infection in vivo Finally, similar cyclic lipopeptides had no effect on CoV infectivity, and the inhibitory effect of surfactin extended broadly to enveloped viruses, including influenza, Ebola, Zika, Nipah, chikungunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses. Overall, our results indicate that peptidoglycan-associated surfactin has broad viricidal activity and suggest that bacteria by-products may negatively modulate virus infection.IMPORTANCE In this article, we consider a role for bacteria in shaping coronavirus infection. Taking cues from studies of enteric viruses, we initially investigated how bacterial surface components might improve CoV infection. Instead, we found that peptidoglycan-associated surfactin is a potent viricidal compound that disrupts virion integrity with broad activity against enveloped viruses. Our results indicate that interactions with commensal bacterial may improve or disrupt viral infections, highlighting the importance of understanding these microbial interactions and their implications for viral pathogenesis and treatment.

Original languageEnglish (US)
JournalJournal of virology
Volume93
Issue number22
DOIs
StatePublished - Nov 15 2019

Fingerprint

lipopeptides
Lipopeptides
surfactin
Peptidoglycan
peptidoglycans
pathogenicity
infection
Lipopolysaccharides
lipopolysaccharides
Enterovirus
Virus Diseases
Infection
Virion
virion
viruses
Crimean-Congo hemorrhagic fever virus
Coronavirus Infections
Microbial Interactions
Anti-Bacterial Agents
Viruses

Keywords

  • coronavirus
  • cyclic lipopeptide
  • MERS-CoV
  • microbiome
  • SARS-CoV
  • surfactin

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity. / Johnson, Bryan A.; Hage, Adam; Kalveram, Birte; Mears, Megan; Plante, Jessica A.; Rodriguez, Sergio E.; Ding, Zhixia; Luo, Xuemei; Bente, Dennis; Bradrick, Shelton S.; Freiberg, Alexander N.; Popov, Vsevolod; Rajsbaum, Ricardo; Rossi, Shannan; Russell, William K.; Menachery, Vineet D.

In: Journal of virology, Vol. 93, No. 22, 15.11.2019.

Research output: Contribution to journalArticle

Johnson, Bryan A. ; Hage, Adam ; Kalveram, Birte ; Mears, Megan ; Plante, Jessica A. ; Rodriguez, Sergio E. ; Ding, Zhixia ; Luo, Xuemei ; Bente, Dennis ; Bradrick, Shelton S. ; Freiberg, Alexander N. ; Popov, Vsevolod ; Rajsbaum, Ricardo ; Rossi, Shannan ; Russell, William K. ; Menachery, Vineet D. / Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity. In: Journal of virology. 2019 ; Vol. 93, No. 22.
@article{00fff0364179456fb517406e8b6706d7,
title = "Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity",
abstract = "Enteric viruses exploit bacterial components, including lipopolysaccharides (LPS) and peptidoglycan (PG), to facilitate infection in humans. Because of their origin in the bat enteric system, we wondered if severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome CoV (MERS-CoV) also use bacterial components to modulate infectivity. To test this question, we incubated CoVs with LPS and PG and evaluated infectivity, finding no change following LPS treatment. However, PG from Bacillus subtilis reduced infection >10,000-fold, while PG from other bacterial species failed to recapitulate this. Treatment with an alcohol solvent transferred inhibitory activity to the wash, and mass spectrometry revealed surfactin, a cyclic lipopeptide antibiotic, as the inhibitory compound. This antibiotic had robust dose- and temperature-dependent inhibition of CoV infectivity. Mechanistic studies indicated that surfactin disrupts CoV virion integrity, and surfactin treatment of the virus inoculum ablated infection in vivo Finally, similar cyclic lipopeptides had no effect on CoV infectivity, and the inhibitory effect of surfactin extended broadly to enveloped viruses, including influenza, Ebola, Zika, Nipah, chikungunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses. Overall, our results indicate that peptidoglycan-associated surfactin has broad viricidal activity and suggest that bacteria by-products may negatively modulate virus infection.IMPORTANCE In this article, we consider a role for bacteria in shaping coronavirus infection. Taking cues from studies of enteric viruses, we initially investigated how bacterial surface components might improve CoV infection. Instead, we found that peptidoglycan-associated surfactin is a potent viricidal compound that disrupts virion integrity with broad activity against enveloped viruses. Our results indicate that interactions with commensal bacterial may improve or disrupt viral infections, highlighting the importance of understanding these microbial interactions and their implications for viral pathogenesis and treatment.",
keywords = "coronavirus, cyclic lipopeptide, MERS-CoV, microbiome, SARS-CoV, surfactin",
author = "Johnson, {Bryan A.} and Adam Hage and Birte Kalveram and Megan Mears and Plante, {Jessica A.} and Rodriguez, {Sergio E.} and Zhixia Ding and Xuemei Luo and Dennis Bente and Bradrick, {Shelton S.} and Freiberg, {Alexander N.} and Vsevolod Popov and Ricardo Rajsbaum and Shannan Rossi and Russell, {William K.} and Menachery, {Vineet D.}",
year = "2019",
month = "11",
day = "15",
doi = "10.1128/JVI.01282-19",
language = "English (US)",
volume = "93",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "22",

}

TY - JOUR

T1 - Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity

AU - Johnson, Bryan A.

AU - Hage, Adam

AU - Kalveram, Birte

AU - Mears, Megan

AU - Plante, Jessica A.

AU - Rodriguez, Sergio E.

AU - Ding, Zhixia

AU - Luo, Xuemei

AU - Bente, Dennis

AU - Bradrick, Shelton S.

AU - Freiberg, Alexander N.

AU - Popov, Vsevolod

AU - Rajsbaum, Ricardo

AU - Rossi, Shannan

AU - Russell, William K.

AU - Menachery, Vineet D.

PY - 2019/11/15

Y1 - 2019/11/15

N2 - Enteric viruses exploit bacterial components, including lipopolysaccharides (LPS) and peptidoglycan (PG), to facilitate infection in humans. Because of their origin in the bat enteric system, we wondered if severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome CoV (MERS-CoV) also use bacterial components to modulate infectivity. To test this question, we incubated CoVs with LPS and PG and evaluated infectivity, finding no change following LPS treatment. However, PG from Bacillus subtilis reduced infection >10,000-fold, while PG from other bacterial species failed to recapitulate this. Treatment with an alcohol solvent transferred inhibitory activity to the wash, and mass spectrometry revealed surfactin, a cyclic lipopeptide antibiotic, as the inhibitory compound. This antibiotic had robust dose- and temperature-dependent inhibition of CoV infectivity. Mechanistic studies indicated that surfactin disrupts CoV virion integrity, and surfactin treatment of the virus inoculum ablated infection in vivo Finally, similar cyclic lipopeptides had no effect on CoV infectivity, and the inhibitory effect of surfactin extended broadly to enveloped viruses, including influenza, Ebola, Zika, Nipah, chikungunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses. Overall, our results indicate that peptidoglycan-associated surfactin has broad viricidal activity and suggest that bacteria by-products may negatively modulate virus infection.IMPORTANCE In this article, we consider a role for bacteria in shaping coronavirus infection. Taking cues from studies of enteric viruses, we initially investigated how bacterial surface components might improve CoV infection. Instead, we found that peptidoglycan-associated surfactin is a potent viricidal compound that disrupts virion integrity with broad activity against enveloped viruses. Our results indicate that interactions with commensal bacterial may improve or disrupt viral infections, highlighting the importance of understanding these microbial interactions and their implications for viral pathogenesis and treatment.

AB - Enteric viruses exploit bacterial components, including lipopolysaccharides (LPS) and peptidoglycan (PG), to facilitate infection in humans. Because of their origin in the bat enteric system, we wondered if severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome CoV (MERS-CoV) also use bacterial components to modulate infectivity. To test this question, we incubated CoVs with LPS and PG and evaluated infectivity, finding no change following LPS treatment. However, PG from Bacillus subtilis reduced infection >10,000-fold, while PG from other bacterial species failed to recapitulate this. Treatment with an alcohol solvent transferred inhibitory activity to the wash, and mass spectrometry revealed surfactin, a cyclic lipopeptide antibiotic, as the inhibitory compound. This antibiotic had robust dose- and temperature-dependent inhibition of CoV infectivity. Mechanistic studies indicated that surfactin disrupts CoV virion integrity, and surfactin treatment of the virus inoculum ablated infection in vivo Finally, similar cyclic lipopeptides had no effect on CoV infectivity, and the inhibitory effect of surfactin extended broadly to enveloped viruses, including influenza, Ebola, Zika, Nipah, chikungunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses. Overall, our results indicate that peptidoglycan-associated surfactin has broad viricidal activity and suggest that bacteria by-products may negatively modulate virus infection.IMPORTANCE In this article, we consider a role for bacteria in shaping coronavirus infection. Taking cues from studies of enteric viruses, we initially investigated how bacterial surface components might improve CoV infection. Instead, we found that peptidoglycan-associated surfactin is a potent viricidal compound that disrupts virion integrity with broad activity against enveloped viruses. Our results indicate that interactions with commensal bacterial may improve or disrupt viral infections, highlighting the importance of understanding these microbial interactions and their implications for viral pathogenesis and treatment.

KW - coronavirus

KW - cyclic lipopeptide

KW - MERS-CoV

KW - microbiome

KW - SARS-CoV

KW - surfactin

UR - http://www.scopus.com/inward/record.url?scp=85074308329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074308329&partnerID=8YFLogxK

U2 - 10.1128/JVI.01282-19

DO - 10.1128/JVI.01282-19

M3 - Article

C2 - 31462558

AN - SCOPUS:85074308329

VL - 93

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 22

ER -